Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia: Background. The outcome of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) beyond the second-line has not been studied in Saudi Arabia. Therefore, this multicenter retrospective analysis was conducted to evaluate the efficacy of FTD/TPI. Methods. This multicenter retrospective analysis included five centers in Saudi Arabia. FTD/TPI was administered to all the patients beyond the oxaliplatin- and irinotecan-based chemotherapy regimens. The electronic medical records were reviewed, and progression-free survival (PFS) and overall survival (OS) were determined. Results. The study included 100 patients with a mean age of years. The overall response to FTD/TPI was 4%. The median PFS was 4 months (95% confidence interval (CI) 3.487–4.513), and the median OS was 11 months (95% CI, 9.226–12.771). In a Cox regression analysis of the independent predictors for PFS, advanced stage of the disease ( ; HR, 2.614; and CI, 1.102–7.524), presence of lymph node metastasis ( ; HR, 3.664; and 95% CI, 1.187–8.650), and >2 metastatic sites ( ; HR, 1.723; and 95% CI, 1.089–2.727) were independent factors predicting disease progression. The Cox regression analysis confirmed that years ( ; HR, 1.667; and 95%, 1.097–3.100), advanced disease stage ( ; HR, 1.283; and 95% CI, 1.035–2.940), prior use of adjuvant chemotherapy ( ; HR, 0.892; and 95% CI, 0.481–0.994), liver metastasis ( ; HR, 2.015; and 95% CI, 1.091–3.720), >2 metastatic sites ( ; HR, 1.248; and 95% CI, 1.036–1.846), development of neutropenia after receiving first cycle of FTD/TPI ( ; HR, 1.505; and 95% CI, 1.064–2.167), and increased number of FTD/TPI cycles ( ; HR, 0.769; and 95% CI, 0.664–0.891) were independent variables for OS. Conclusion. Treatment with FTD/TPI is feasible and effective in daily clinical practice in Saudi Arabian patients. The risk of progression increased with advanced disease stage, lymph node metastasis, bone metastasis, and metastasis to >2 sites.
Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC. Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity. Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m2 capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; ). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS ( ), better performance status ( ), and absence of brain metastasis ( ) were associated with prolonged progression-free survival. Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.
1 April 2023 in The Egyptian Journal of Plastic and Reconstructive Surgery
Background: Thumb tip and pulp defects might causeserious morbidity for the patient. Loss of the highly specialisedand sensate pulp can have a major impact on overall handfunction in addition to the cosmetic abnormality.Objective: To highlight the functional, aesthetic outcomesand postoperative complication for these surgical techniquesin the treatment of thumb tip injuries.Material and Methods: A comprehensive search of theliterature via electronic databases including Pub Med/ Medline,Cochrane, Web of Science and Google Scholar. An initialsearch was carried out using keywords: Thumb tip injury,thumb tip amputation, Surgical flaps and Reconstruction.Studies of different modalities were analyzed and comparedregarding the aesthetic outcome, sensory outcome, range ofmotion and rate of complications. Hand surgeons were contactedto help identifying other published and unpublishedrelevant studies.Results: The main point strength in the current study isthat we have systematically analyzed a wide range of localand regional thumb tip reconstruction options.Conclusion: Local and regional options are comparablein terms of sensory, motor, and aesthetic scores, and patientsatisfaction. However local options are associated with significantlyhigher complication rates
1 April 2022 in The Egyptian Journal of Plastic and Reconstructive Surgery
PURPOSE: Gestational trophoblastic neoplasia (GTN) is a highly curable malignancy classified using the International Federation of Gynecology and Obstetrics (FIGO)/WHO scoring system into low-risk (score 0-6) and high-risk (score ≥ 7) categories. Although single-agent chemotherapy is standard for low-risk GTN, patients with FIGO scores of 5-6 exhibit disproportionately high rates of chemoresistance, raising concerns about current classification and treatment strategies. METHODS: This retrospective analytic study included 162 patients with low-risk GTN treated at a tertiary referral center in Saudi Arabia from 1980 to 2021. Patients were stratified into FIGO score subgroups (0-4 v 5-6), and data on demographics, treatment regimens, outcomes, and chemoresistance were collected. The primary outcome was resistance to first-line chemotherapy. Multivariable logistic regression identified independent predictors of chemoresistance. RESULTS: The median patient age was 35 years, with 64.8% age 40 years and younger. Hydatidiform mole was the most common antecedent pregnancy (88.9%), and 30.9% had FIGO scores of 5-6. First-line treatment included single-agent chemotherapy (74.7%) and multiagent regimens (25.3%). Although all patients achieved complete remission, 26.5% exhibited chemoresistance to first-line treatment, significantly associated with treatment before the year 2000, higher FIGO scores, and single-agent chemotherapy. On multivariable analysis, FIGO scores of 5-6 (odds ratio [OR], 2.6; P = .02) and single-agent chemotherapy (OR, 0.11; P = .007) were independent predictors of resistance. β-human chorionic gonadotropin (hCG) level was the only FIGO component independently linked to chemoresistance. Relapse occurred in 5.4% of cases. CONCLUSION: Patients with FIGO scores of 5-6 and high β-hCG levels had increased resistance to first-line therapy. β-hCG was the strongest independent predictor. These findings highlight the need to reassess treatment strategies for this subgroup.